Keywords: هیپر فسفاتمی; Phosphate binder; calcium acetate; lanthanum carbonate; sevelamer carbonate; sevelamer hydrochloride; hyperphosphatemia; chronic kidney disease (CKD); end-stage renal disease (ESRD); dialysis; drug efficacy; drug cost-effectiveness; health care costs; Med
مقالات ISI هیپر فسفاتمی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: هیپر فسفاتمی; chronic kidney disease; dietary phosphate; hyperphosphatemia; intestinal phosphate absorption; phosphate binders;
Keywords: هیپر فسفاتمی; Hyperphosphatemia; Lanthanum carbonate; Scanning electron microscopy analysis; Esophagogastroduodenoscopy;
Keywords: هیپر فسفاتمی; calcium carbonate; combination therapy; hemodialysis; hyperphosphatemia; sucroferric oxyhydroxide (PA21);
Keywords: هیپر فسفاتمی; Phosphorus; Phosphate; Anion; Hypophosphatemia; Hyperphosphatemia;
Keywords: هیپر فسفاتمی; Chronic kidney disease; Hyperphosphatemia; Phosphaturia; Phosphate binders; Captor de fósforo; Enfermedad renal crónica; Fosfaturia; Hiperfosfatemia;
Keywords: هیپر فسفاتمی; Tumor lysis syndrome; Hyperuricemia; Hyperphosphatemia; Hyperkalemia; Malignant cell metabolism;
Keywords: هیپر فسفاتمی; Hemodialysis (HD); in-center nocturnal HD; nocturnal HD; conventional HD; left ventricular hypertrophy; cardiac geometry; blood pressure; mineral metabolism; hyperphosphatemia; intradialytic hypotension; hospitalization; mortality; intensive HD; dialysis
Keywords: هیپر فسفاتمی; FGF23; α-Klotho; Hypophosphatemia; Hyperphosphatemia; Rickets; Osteomalacia;
Keywords: هیپر فسفاتمی; Lanthanum carbonate; phosphate binder; foreign-body reaction; histiocytosis; upper gastrointestinal bleed; dialysis; hyperphosphatemia; end-stage renal disease (ESRD);
Keywords: هیپر فسفاتمی; Serum phosphorus; hyperphosphatemia; risk factor; all-cause mortality; sex; age; normal kidney function;
Keywords: هیپر فسفاتمی; Renal secondary hyperparathyroidism; Fibroblast growth factor 23; Renal osteodystrophy; Hyperphosphatemia;
Keywords: هیپر فسفاتمی; Apoptosis; Bone morphogenetic protein 4; Extracellular regulated protein kinases; Endothelial cells; Hyperphosphatemia
Keywords: هیپر فسفاتمی; Chronic kidney disease; Hemodialysis; Hyperphosphatemia; Renal replacement therapy; Uremia
Keywords: هیپر فسفاتمی; chronic kidney disease; hyperphosphatemia; magnesium;
Keywords: هیپر فسفاتمی; Hemodialysis; hyperphosphatemia; ferric citrate; sevelamer carbonate; calcium acetate; phosphate binder; mineral bone disease; protein-energy wasting (PEW)/inflammation; adverse events; safety; end-stage renal disease (ESRD);
Keywords: هیپر فسفاتمی; Calcification; Chronic kidney disease; FGF-23; Hyperphosphatemia; Phosphate binders; Prognosis
Keywords: هیپر فسفاتمی; Hyperphosphatemia; Dietary phosphorus; Food additives; Phosphate binders; Chronic kidney disease
Keywords: هیپر فسفاتمی; Calcium; clinical epidemiology; hemodialysis; hyperparathyroidism; hyperphosphatemia; mineral metabolism; death; end-stage renal disease; parathyroid hormone (PTH);
Keywords: هیپر فسفاتمی; cost-minimization; daily dose; end-stage renal disease; hyperphosphatemia; lanthanum carbonate; phosphate binder; sevelamer hydrochloride;
Keywords: هیپر فسفاتمی; cost-effectiveness; dose-relativity; end-stage renal disease; hyperphosphatemia; lanthanum carbonate; phosphate binder; sevelamer hydrochloride; tablet burden;
Keywords: هیپر فسفاتمی; Hypercalcemia; Hypocalcemia; Hypermagnesemia; Hypomagnesemia; Hyperphosphatemia; Hypophosphatemia;
Keywords: هیپر فسفاتمی; hyperphosphatemia; phosphate binders; vascular calcification;
Keywords: هیپر فسفاتمی; dialysis; hyperparathyroidism; hyperphosphatemia; mineral metabolism; mortality risk; phosphate binders;
Keywords: هیپر فسفاتمی; cost-minimization; hyperphosphatemia; lanthanum carbonate; patients not on dialysis; sevelamer
Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation
Keywords: هیپر فسفاتمی; Case report; fibroblast growth factor 23 (FGF-23); FGF23 mutation; hemodialysis; hyperphosphatemia; genetic disease; metabolic disorder; mutation; tumoral calcinosis; extra-osseous calcifications;
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
Keywords: هیپر فسفاتمی; end-stage renal disease; hemodialysis; hyperphosphatemia; NPT-IIb inhibitor; pharmacokinetics; phase 1 trial;
Phosphate Kinetic Models in Hemodialysis: A Systematic Review
Keywords: هیپر فسفاتمی; Compartment modeling; hyperphosphatemia; inorganic phosphate; phosphate kinetics; phosphate metabolism; chronic kidney disease (CKD); end-stage renal disease (ESRD); hemodialysis (HD); systematic review;
Oxyhydroxyde sucroferrique, un nouveau chélateur des phosphates à base de fer. Quelle utilisation chez le patient dialysé ?
Keywords: هیپر فسفاتمی; Oxyhydroxyde sucroferrique; Hyperphosphatémie; Pouvoir chélateur; Observance; Dialyse; Sucroferric oxyhydroxide; Hyperphosphatemia; Binding capacity; Adherence; Dialysis;
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
Keywords: هیپر فسفاتمی; CKD; ERI; ESA; ferric citrate hydrate; ferritin; hyperphosphatemia;
Cómo estimar la eficacia de un captor del fósforo
Keywords: هیپر فسفاتمی; Captor de fósforo; Enfermedad renal crónica; Fosfaturia; Hiperfosfatemia; Chronic kidney disease; Hyperphosphatemia; Phosphaturia; Phosphate binders;
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters
Keywords: هیپر فسفاتمی; bone mineral density; calcium; dialysis; hyperparathyroidism; hyperphosphatemia; KDIGO CKD-MBD Guideline; kidney transplantation;
Novel functions of circulating Klotho
Keywords: هیپر فسفاتمی; Hyperphosphatemia; Hypophosphatemia; cKL; FGF23; Phosphate; Vascular calcification;
Genetic diseases resulting from disordered FGF23/klotho biology
Keywords: هیپر فسفاتمی; FGF23; Klotho; Hypophosphatemia; Hyperphosphatemia; Tumoral calcinosis; GALNT3; PHEX;
Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics
Keywords: هیپر فسفاتمی; FGF-23; Genetics; Hypophosphatemia; Hyperphosphatemia; Klotho; Tumoral calcinosis;
Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders
Keywords: هیپر فسفاتمی; Hyperphosphatemia; phosphate levels; dialysis; dialytic phosphate removal; phosphate binders; binder efficacy; enteral phosphate absorption; vitamin D; individual variation; treatment adherence; dietary phosphate;
CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
Keywords: هیپر فسفاتمی; FGF-23; Hyperphosphatemia; Vascular calcification; Hyperparathyroidism; Metabolic acidosis;
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China
Keywords: هیپر فسفاتمی; calcium-based binders; China; cost-effectiveness analysis; hyperphosphatemia; sevelamer;
Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
Keywords: هیپر فسفاتمی; Arteriovenous fistula; Hemodialysis; Hyperphosphatemia
Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis
Keywords: هیپر فسفاتمی; Hyperphosphatemia; Peritoneal dialysis; Dietary intervention; Dietary phosphate intake; Cooking method;
Hyperphosphatemia induces cellular senescence in human aorta smooth muscle cells through integrin linked kinase (ILK) up-regulation
Keywords: هیپر فسفاتمی; ILK; integrin linked kinase; BGP; β-Glycerophosphate; SA-β-G; alsenescence-associated-β-galactosidase; SAP; Ssenescence associated secretory phenotype; HASMC; human aorta smooth muscle cell; C12FDG; fluorogenic substrate 5-dodecanoylaminofluorescein di
Niacin and Progression of CKD
Keywords: هیپر فسفاتمی; Niacin; chronic kidney disease; HDL function; hyperphosphatemia; cardiovascular disease; phosphorus absorption;
Microtubule stabilization attenuates vascular calcification through the inhibition of osteogenic signaling and matrix vesicle release
Keywords: هیپر فسفاتمی; Vascular smooth muscle cell; Ectopic calcification; Hyperphosphatemia; Microtubule
Comparative Effectiveness of Calcium Acetate and Sevelamer on Clinical Outcomes in Elderly Hemodialysis Patients Enrolled in Medicare Part D
Keywords: هیپر فسفاتمی; Medicare Part D; hyperphosphatemia; phosphate binders; dialysis; calcium acetate; sevelamer; end-stage renal disease (ESRD); mortality; cardiovascular disease; elderly; coronary calcification; comparative effectiveness;
Clinical TrialA phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
Keywords: هیپر فسفاتمی; adherence; dialysis; hyperphosphatemia; phosphate binder; PA21; sevelamer;
Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?
Keywords: هیپر فسفاتمی; Calcium; hyperphosphatemia; vitamin D; uremic toxins; FGF23; klotho; PTH
Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer
Keywords: هیپر فسفاتمی; Hyperphosphatemia; Phosphate binder; Phosphate absorption; Poly (allylamine) polymer;
Novel cyclodextrin nanosponges for delivery of calcium in hyperphosphatemia
Keywords: هیپر فسفاتمی; Nanosponges; Calcium carbonate; Hyperphosphatemia; Phosphate binding;
Phoxilium vs Hemosol-B0 for continuous renal replacement therapy in acute kidney injury
Keywords: هیپر فسفاتمی; Acute kidney injury; Continuous renal replacement therapy; Hemosol-B0; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Metabolic acidosis; Phosphate-containing solution; Phoxilium; Nutrition; Electrolyte abnormalities; Acid-base balance; Critical illne
Assay development of inducible human renal phosphate transporter Npt2A (SLC34A1) in Flp-In-Trex-HEK293 cells
Keywords: هیپر فسفاتمی; Npt2A; SLC34A1; Assay development; Phosphate uptake; Specific inhibitor; Hyperphosphatemia;